Table 3.

Proportional hazards models to risk of malignant neoplasms associated with BMP treatment.

Site of Cancer	Univariate HR for rhBMP	Lower 95% CI	Upper 95% CI	P Value	Multivariate HR for rhBMP	Lower 95% CI	Upper 95% CI	P Value
Bone	0	0	0		0	0	0
Brain and other central nervous system	0.22	0.03	1.61	.138	0.26	0.04	1.92	.188
Breast	0.79	0.48	1.31	.359	0.86	0.52	1.43	.560
Cervix uteri	0.00	0.00	–	.992	0.00	0.00	–	.991
Colon and rectum	0.72	0.32	1.64	.438	0.90	0.39	2.05	.794
Corpus uteri	0.29	0.04	2.12	.223	0.29	0.04	2.14	.226
Esophagus	0.00	0.00	–	.990	0.00	0.00	–	.994
Hodgkins lymphoma	1.23	0.38	3.99	.733	1.24	0.38	4.08	.725
Non-Hodgkins lymphoma	0.72	0.43	1.22	.222	0.72	0.43	1.22	.218
Kaposi sarcoma	0.00	0.00	–	.993	0.00	0.00	–	.996
Kidney and renal pelvis	0.78	0.34	1.76	.543	0.71	0.31	1.62	.414
Larynx	0.00	0.00	–	.997	0.00	0.00	–	.999
Leukemia	0.77	0.34	1.75	.530	0.65	0.28	1.48	.301
Liver and intrahepatic bile duct	0.00	0.00	–	.990	0.00	0.00	–	.994
Lung and bronchus	1.18	0.47	2.95	.719	1.05	0.42	2.65	.913
Melanoma	0.72	0.37	1.41	.336	0.70	0.36	1.38	.302
Mesothelioma	0.00	0.00	–	.997	0.00	0.00	–	.999
Myeloma	0.70	0.33	1.50	.358	0.64	0.30	1.38	.254
Oral cavity and pharynx	0.59	0.08	4.33	.601	0.67	0.09	5.03	.699
Ovary	0.71	0.17	2.96	.643	0.72	0.17	3.05	.660
Pancreas	0.00	0.00	–	.984	0.00	0.00	–	.990
Prostate	0.74	0.35	1.58	.433	0.72	0.33	1.54	.394
Stomach	0	0.00		.988	0.00	0.00		.992
Testis	1.94	0.24	15.80	.536	2.03	0.24	17.48	.519
Thyroid	0.53	0.17	1.68	.282	0.50	0.16	1.60	.245
Urinary bladder	0.51	0.13	2.10	.353	0.58	0.14	2.40	.453

Abbreviations: HR, hazard ratio; rhBMP, recombinant human bone morphogenic protein. Dashes in cells indicate that that the confidence interval could not be estimated because of sample size.